Ifupinostat
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med IncSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Relapsed/Refractory Diffuse Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifosfamide BeBetter Med Inc | Phase 3 | BB |
Hmpl-760 Hutchmed | Phase 3 | BB |
Ifupinostat Hydrochloride For BeBetter Med Inc | Phase 3 | B |
Same molecule, other indications
Ifupinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →